October 30, 2015

October 30, 2015

Episodes

Specialty:

All

Year:

All

EP. 1: FDA Approves MM-398, T-VEC, and Trabectedin, Cabozantinib RCC FDA Submission Started, New Pembrolizumab Data, and More

October 31st 2015

Trending on OncLive

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors